|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
Cancers in 185 Countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Morris LG, Tuttle RM and Davies L:
Changing trends in the incidence of thyroid cancer in the United
States. JAMA Otolaryngol Head Neck Surg. 142:709–711.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nikiforov YE, Seethala RR, Tallini G,
Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan
A, Kakudo K, et al: Nomenclature revision for encapsulated
follicular variant of papillary thyroid carcinoma: A paradigm shift
to reduce overtreatment of indolent tumors. JAMA Oncol.
2:1023–1029. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Laha D, Nilubol N and Boufraqech M: New
Therapies for Advanced Thyroid Cancer. Front Endocrinol (Lausanne).
11(82)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Nikiforov YE: Thyroid carcinoma: Molecular
pathways and therapeutic targets. Mod Pathol. 21 (Suppl 2):S37–S43.
2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Dvorak K, Aggeler B, Palting J, McKelvie
P, Ruszkiewicz A and Waring P: Immunohistochemistry with the
anti-BRAF V600E (VE1) antibody: Impact of pre-analytical conditions
and concordance with DNA sequencing in colorectal and papillary
thyroid carcinoma. Pathology. 46:509–517. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wan PT, Garnett MJ, Roe SM, Lee S,
Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ,
Barford D, et al: Cancer Genome Project: Mechanism of activation of
the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Cell. 116:855–867. 2004.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Oh HS, Kwon H, Park S, Kim M, Jeon MJ, Kim
TY, Shong YK, Kim WB, Choi J, Kim WG, et al: Comparison of
Immunohistochemistry and Direct Sanger Sequencing for Detection of
the BRAF(V600E) Mutation in Thyroid Neoplasm. Endocrinol Metab
(Seoul). 33:62–69. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Xing M: BRAF mutation in thyroid cancer.
Endocr Relat Cancer. 12:245–262. 2005.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kim TY, Kim WB, Rhee YS, Song JY, Kim JM,
Gong G, Lee S, Kim SY, Kim SC, Hong SJ, et al: The BRAF mutation is
useful for prediction of clinical recurrence in low-risk patients
with conventional papillary thyroid carcinoma. Clin Endocrinol
(Oxf). 65:364–368. 2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kondo T, Ezzat S and Asa SL: Pathogenetic
mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer.
6:292–306. 2006.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mo SP, Coulson JM and Prior IA: RAS
variant signalling. Biochem Soc Trans. 46:1325–1332.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Takai Y, Sasaki T and Matozaki T: Small
GTP-binding proteins. Physiol Rev. 81:153–208. 2001.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Castellano E and Santos E: Functional
specificity of ras isoforms: So similar but so different. Genes
Cancer. 2:216–231. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chakladar J, Li WT, Bouvet M, Chang EY,
Wang-Rodriguez J and Ongkeko WM: Papillary thyroid carcinoma
variants are characterized by co-dysregulation of immune and cancer
associated genes. Cancers (Basel). 11(1179)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Motoi N, Sakamoto A, Yamochi T, Horiuchi
H, Motoi T and Machinami R: Role of ras mutation in the progression
of thyroid carcinoma of follicular epithelial origin. Pathol Res
Pract. 196:1–7. 2000.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Garcia-Rostan G, Zhao H, Camp RL, Pollan
M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J and Tallini G:
ras mutations are associated with aggressive tumor phenotypes and
poor prognosis in thyroid cancer. J Clin Oncol. 21:3226–3235.
2003.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ezzat S, Zheng L, Kolenda J, Safarian A,
Freeman JL and Asa SL: Prevalence of activating ras mutations in
morphologically characterized thyroid nodules. Thyroid. 6:409–416.
1996.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhu Z, Gandhi M, Nikiforova MN, Fischer AH
and Nikiforov YE: Molecular profile and clinical-pathologic
features of the follicular variant of papillary thyroid carcinoma.
An unusually high prevalence of ras mutations. Am J Clin Pathol.
120:71–77. 2003.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hara H, Fulton N, Yashiro T, Ito K,
DeGroot LJ and Kaplan EL: N-ras mutation: An independent prognostic
factor for aggressiveness of papillary thyroid carcinoma. Surgery.
116:1010–1016. 1994.PubMed/NCBI
|
|
21
|
Howell GM, Hodak SP and Yip L: RAS
mutations in thyroid cancer. Oncologist. 18:926–932.
2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Khan MS, Pandith AA, Ul Hussain M, Iqbal
M, Khan NP, Wani KA, Masoodi SR and Mudassar S: Lack of mutational
events of RAS genes in sporadic thyroid cancer but high risk
associated with HRAS T81C single nucleotide polymorphism
(case-control study). Tumour Biol. 34:521–529. 2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang Y, Gao W, Guo Y and Peng C: The role
of HRAS rs12628 polymorphism in cancer risks: Evidence from a
meta-analysis of 19 case-control studies. Int J Clin Exp Med.
10:2386–2396. 2017.
|
|
24
|
Castro P, Soares P, Gusmão L, Seruca R and
Sobrinho-Simões M: H-RAS 81 polymorphism is significantly
associated with aneuploidy in follicular tumors of the thyroid.
Oncogene. 25:4620–4627. 2006.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Khan MS, Pandith AA, Azad N, Hussain MU,
Masoodi SR, Wani KA, Andrabi KI and Mudassar S: Impact of molecular
alterations of BRAF in the pathogenesis of thyroid cancer.
Mutagenesis. 29:131–137. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Morrison DK: MAP kinase pathways. Cold
Spring Harb Perspect Biol. 4(a011254)2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Garnett MJ and Marais R: Guilty as
charged: B-RAF is a human oncogene. Cancer Cell. 6:313–319.
2004.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Cantwell-Dorris ER, O'Leary JJ and Sheils
OM: BRAFV600E: Implications for carcinogenesis and molecular
therapy. Mol Cancer Ther. 10:385–394. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Pakneshan S, Salajegheh A, Smith RA and
Lam AK: Clinicopathological relevance of BRAF mutations in human
cancer. Pathology. 45:346–356. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sahin IH and Klostergaard J: BRAF
mutations as actionable targets: A paradigm shift in the management
of colorectal cancer and novel avenues. JCO Oncol Pract: Jun 2,
2021 (Epub ahead of print). doi: 10.1200/OP.21.00160.
|
|
32
|
Kebebew E and Clark OH: Differentiated
thyroid cancer: ‘complete’ rational approach. World J Surg.
24:942–951. 2000.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kim J, Giuliano AE, Turner RR, Gaffney RE,
Umetani N, Kitago M, Elashoff D and Hoon DS: Lymphatic mapping
establishes the role of BRAF gene mutation in papillary thyroid
carcinoma. Ann Surg. 244:799–804. 2006.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lupi C, Giannini R, Ugolini C, Proietti A,
Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, et
al: Association of BRAF V600E mutation with poor
clinicopathological outcomes in 500 consecutive cases of papillary
thyroid carcinoma. J Clin Endocrinol Metab. 92:4085–4090.
2007.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Abdullah MI, Junit SM, Ng KL, Jayapalan
JJ, Karikalan B and Hashim OH: Papillary Thyroid Cancer: Genetic
Alterations and Molecular Biomarker Investigations. Int J Med Sci.
16:450–460. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Adeniran AJ, Zhu Z, Gandhi M, Steward DL,
Fidler JP, Giordano TJ, Biddinger PW and Nikiforov YE: Correlation
between genetic alterations and microscopic features, clinical
manifestations, and prognostic characteristics of thyroid papillary
carcinomas. Am J Surg Pathol. 30:216–222. 2006.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Xing M, Westra WH, Tufano RP, Cohen Y,
Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et
al: BRAF mutation predicts a poorer clinical prognosis for
papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379.
2005.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kebebew E, Weng J, Bauer J, Ranvier G,
Clark OH, Duh QY, Shibru D, Bastian B and Griffin A: The prevalence
and prognostic value of BRAF mutation in thyroid cancer. Ann Surg.
246:466–471. 2007.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Liu D, Hu S, Hou P, Jiang D, Condouris S
and Xing M: Suppression of BRAF/MEK/MAP kinase pathway restores
expression of iodide-metabolizing genes in thyroid cells expressing
the V600E BRAF mutant. Clin Cancer Res. 13:1341–1349.
2007.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Makboul R, Mostafa NM, El-Deek HEM,
Aboulhagag NA, Shehata MR and Abdelhafez YG: Do BRAFV600E mutation
and sodium-iodide symporter expression affect the response to
radioactive iodine therapy in patients with papillary thyroid
carcinoma? Nucl Med Commun. 41:416–425. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Durante C, Puxeddu E, Ferretti E, Morisi
R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A,
et al: BRAF mutations in papillary thyroid carcinomas inhibit genes
involved in iodine metabolism. J Clin Endocrinol Metab.
92:2840–2843. 2007.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Li ZN, Zhao L, Yu LF and Wei MJ: BRAF and
KRAS mutations in metastatic colorectal cancer: Future perspectives
for personalized therapy. Gastroenterol Rep (Oxf). 8:192–205.
2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Oikonomou E, Koustas E, Goulielmaki M and
Pintzas A: BRAF vs. RAS oncogenes: Are mutations of the same
pathway equal? Differential signalling and therapeutic
implications. Oncotarget. 5:11752–11777. 2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Shi YF, Zou MJ, Schmidt H, Juhasz F,
Stensky V, Robb D and Farid NR: High rates of ras codon 61 mutation
in thyroid tumors in an iodide-deficient area. Cancer Res.
51:2690–2693. 1991.PubMed/NCBI
|
|
45
|
Vuong HG, Kondo T, Oishi N, Nakazawa T,
Mochizuki K, Inoue T, Tahara I, Kasai K, Hirokawa M, Tran TM, et
al: Genetic alterations of differentiated thyroid carcinoma in
iodine-rich and iodine-deficient countries. Cancer Med.
5:1883–1889. 2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Jung CK, Kim Y, Jeon S, Jo K, Lee S and
Bae JS: Clinical utility of EZH1 mutations in the diagnosis of
follicular-patterned thyroid tumors. Hum Pathol. 81:9–17.
2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Zhang Y, Jin M, Liu B, Ma X, Yao K, Li Q
and Chen K: Association between H-RAS T81C genetic polymorphism and
gastrointestinal cancer risk: A population based case-control study
in China. BMC Cancer. 8(256)2008.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Pandith AA, Shah ZA, Khan NP, Baba KM,
Wani MS and Siddiqi MA: HRAS T81C polymorphism modulates risk of
urinary bladder cancer and predicts advanced tumors in ethnic
Kashmiri population. Urol Oncol. 31:487–492. 2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Rostami M, Kalaei Z, Pourhoseingholi MA
and Kadivar M: Study on association between H-ras gene polymorphism
and gastric adenocarcinoma risk. Gastroenterol Hepatol Bed Bench.
6:146–151. 2013.PubMed/NCBI
|
|
50
|
Cho A, Chang Y, Ahn J, Shin H and Ryu S:
Cigarette smoking and thyroid cancer risk: A cohort study. Br J
Cancer. 119:638–645. 2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Jee SH, Samet JM, Ohrr H, Kim JH and Kim
IS: Smoking and cancer risk in Korean men and women. Cancer Causes
Control. 15:341–348. 2004.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Navarro Silvera SA, Miller AB and Rohan
TE: Risk factors for thyroid cancer: A prospective cohort study.
Int J Cancer. 116:433–438. 2005.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Dou R, Zhang L, Lu T, Liu D, Mei F, Huang
J and Qian L: Identification of a novel HRAS variant and its
association with papillary thyroid carcinoma. Oncol Lett.
15:4511–4516. 2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Krishna A, Singh S, Singh V, Kumar V,
Singh US and Sankhwar SN: Does Harvey-Ras gene expression lead to
oral squamous cell carcinoma? A clinicopathological aspect. J Oral
Maxillofac Pathol. 22:65–72. 2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Suarez HG, du Villard JA, Severino M,
Caillou B, Schlumberger M, Tubiana M, Parmentier C and Monier R:
Presence of mutations in all three ras genes in human thyroid
tumors. Oncogene. 5:565–570. 1990.PubMed/NCBI
|
|
56
|
Lowy DR and Willumsen BM: Function and
regulation of ras. Annu Rev Biochem. 62:851–891. 1993.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Tomei S, Adams S, Uccellini L, Bedognetti
D, De Giorgi V, Erdenebileg N, Ascierto ML, Reinboth J, Liu Q,
Bevilacqua G, et al: Association between HRAS rs12628 and
rs112587690 polymorphisms with the risk of melanoma in the North
American population. Med Oncol. 29:3456–3461. 2012.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Ni Q, Zhang YJ, Zhang SC, Jin MJ, Ma XY,
Yao KY, Li QL and Chen K: Association between H-ras and L-myc gene
polymorphisms and susceptibility to colorectal cancer. Zhonghua
Zhong Liu Za Zhi. 34:15–20. 2012.PubMed/NCBI(In Chinese).
|
|
59
|
Trepicchio WL and Krontiris TG: Members of
the rel/NF-kappa B family of transcriptional regulatory proteins
bind the HRAS1 minisatellite DNA sequence. Nucleic Acids Res.
20:2427–2434. 1992.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Kotsinas A, Gorgoulis VG, Zacharatos P,
Mariatos G, Kokotas S, Liloglou T, Ikonomopoulos J, Zoumpourlis V,
Kyroudi A, Field JK, et al: Additional characterization of a
hexanucleotide polymorphic site in the first intron of human H-ras
gene: Comparative study of its alterations in non-small cell lung
carcinomas and sporadic invasive breast carcinomas. Cancer Genet
Cytogenet. 126:147–154. 2001.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Sol-Church K, Stabley DL, Nicholson L,
Gonzalez IL and Gripp KW: Paternal bias in parental origin of HRAS
mutations in Costello syndrome. Hum Mutat. 27:736–741.
2006.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Wang Q: Cancer predisposition genes:
Molecular mechanisms and clinical impact on personalized cancer
care: Examples of Lynch and HBOC syndromes. Acta Pharmacol Sin.
37:143–149. 2016.PubMed/NCBI View Article : Google Scholar
|
